CHILDS JOHN W sold $10.7M of MANE (indirect holdings)

CHILDS JOHN W sold 100,000 indirectly-held shares of Veradermics, Inc (MANE) at an average of $107.12 ($106.14–$108.24, $10.71M total) across 3 trades on 2026-08-12.

Original reporting
SEC EDGAR · CHILDS JOHN W
Published Aug 14, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

A director’s open-market sale of 100,000 shares at about $106.14 to $108.24 is disclosed, but there is no accompanying guidance, deal, or operational update.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

The article does not disclose the insider’s cost basis, tax situation, or whether other insiders are selling, limiting inference from this single transaction.

Relevance 7/10Novelty 3/10Timing: filed 2026-08-14 after-hours; sale executed 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Director CHILDS JOHN W sold $10.71M of MANE shares via an open-market sale on 2026-08-12, with holdings after sale at 194,117 shares.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing discloses transaction size, price range, and post-sale holdings, but provides no new company-specific operating or regulatory catalyst.

Market effects

No sector read-through is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • Veradermics, Inc

    Company whose director insider sale is reported on SEC Form 4.

  • CHILDS JOHN W

    Director who sold shares indirectly via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.